Aclidinium bromide for stable chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Ni, Han ^a   Soe, Zay ^b   Moe, Soe ^c  

^a SEGI UNIVERSITY   (Malaysia)

^b UCSI UNIVERSITY   (Malaysia)

^c MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; OXYGEN; PLACEBO; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE DERIVATIVE; TIOTROPIUM BROMIDE; TROPANE DERIVATIVE;

ARTHRALGIA; BACKACHE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY QUESTIONNAIRE; CLINICAL PRACTICE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECONOMIC ASPECT; FATIGUE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HEADACHE; HEALTH CARE QUALITY; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LUNG FUNCTION TEST; OROPHARYNX PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIX MINUTE WALK TEST; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; XEROSTOMIA; AGED; DISEASE COURSE; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES; TROPANES;

EID: 84917689326     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010509.pub2     Document Type: Review

References (185)

1. EUCTR2005-005101-39-AT . A 52-week randomised, double-blind, parallel group, placebo controlled, multicentre clinical trial, to assess the efficacy and safety of 200 μg of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005101-39 (accessed 1 May 2014).
2. Jones PW, Agusti A, Chanez P, Magnussen H, Fabbri L, Maroni J, et al.A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic in patients with COPD: ACCLAIM/COPD 1 [Abstract]. American Thoracic Society International Conference; May 15-20; San Diego. 2009:A6180 [Poster #207].
3. Jones PW, Agusti A, Chanez P, Magnussen H, Fabbri L, Maroni J, et al.Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 12-16; Vienna. 2009:[P2022].
4. Jones PW, Chanez P, Agusti A, Magnussen H, Fabbri L, Caracta C, et al.A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I [Abstract]. Thorax 2009;64 Suppl IV:A168 [P213].
5. Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research 2011;12:55. [PUBMED: 21518460]
6. NCT00363896 . A trial assessing LAS34273 in moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00363896 (accessed 1 May 2014).
7. Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research 2011;12:55. [PUBMED: 21518460]
8. NCT00358436 . Efficacy and safety of LAS 34273 in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00358436 (accessed 1 May 2014).
9. Rennard S, Donohue J, Bateman E, Gross N, Garcia Gil E, Caracta C. ACCLAIM/COPD II: efficacy and safety of aclidinium bromide; a novel long-acting muscarinic antagonist in COPD patients, a phase III study [Abstract]. European Respiratory Society Annual Congress Sep 12-16; Vienna. 2009:[E4351].
10. Rennard S, Donohue J, Bateman E, Gross N, Garcia Gil E, Caracta C. Efficacy and safety of the novel, long-acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II [Abstract]. American Thoracic Society International Conference; May 15-20; San Diego. 2009:A6178 [Poster #205].
11. D'Urzo A, Make BJ, Kerwin EM, Rekeda L, Sanz MT, Caracta C, et al.Safety and tolerability of twice daily aclidinium bromide in COPD patients: ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A1614.
12. D'Urzo A, Make B, Kerwin E, Rekeda L, Garcia Gil E, Caracta C, et al.ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38 (55):729s [P3998].
13. Gelb A, Donohue J, D'Urzo A, Rekeda L, Garcia Gil E, Lateiner J. ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam 2011;38(55):149s [P876].
14. Gelb AF, Donohue JF, D'Urzo A, Rekeda L, Jarreta D, Lateiner J. Improvements in quality of life and dyspnea in COPD patients with twice-daily aclidinium [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A1616.
15. Kerwin E, D'Urzo A, Gelb A, Lakkis H, Garcia Gil E, Caracta C. Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I [Abstract]. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[P1235].
16. Kerwin E, D'Urzo A, Gelb A, Lakkis H, Garcia Gil E, Caracta C. Efficacy and safety of twice-daily aclidinium bromide in patients with COPD: results from ACCORD COPD 1 [Abstract]. Chest 2010;138(4):469A.
17. Kerwin E, Rennard S, Gelb A, Rekeda L, Garcia Gil E, Caracta C. ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:149s [P873].
18. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9(2):90-101. [PUBMED: 22320148]
19. Kerwin EM, Rennard SI, Gelb AF, Rekeda L, Garcia Gil E, Caracta C. Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A1592.
20. NCT00891462 . Efficacy and safety of aclidinium bromide for treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-33). http://www.clinicaltrials.gov/ct2/show/study/NCT00891462 (accessed 1 May 2014).
21. NCT01045161 . To assess the long-term safety, efficacy and tolerability of inhaled aclidinium bromide in the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) (LAS-MD-38). http://clinicaltrials.gov/ct2/show/study/NCT01045161 (accessed 1 May 2014).
22. Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, et al.ACCORD COPD II: A randomised clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clinical Drug Investigation 2013;33(12):893-904.
23. EUCTR2011-001524-38-GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001524-38 (accessed 1 May 2014).
24. NCT01462942 . Long-term efficacy and safety of aclidinium/formoterol fixed-dose combination. http://clinicaltrials.gov/show/NCT01462942 (accessed 1 May 2014).
25. Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E, et al.Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed-dose combination in patients with COPD: the ACLIFORM study. Chest 2014;145:375A.
26. Agusti A, Jones PW, Bateman E, Singh D, Lamarca R, de Miquel G, et al.Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:149s [P874].
27. Bateman ED, Singh D, Jones PW, Agusti A, Lamarca R, de Miquel G, et al.The ATTAIN study: safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:730s [P4005].
28. EUCTR2009-011600-27-CZ . Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011600-27.
29. Jones P, Agusti A, Bateman E, Singh D, Lamarca R, de Miquel G, et al.Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): Reduction in exacerbations as defined by health-care utilisation and the EXACT diary card [Abstract]. Chest 2011;140(4):529A.
30. Jones P, Agusti A, Bateman E, Singh D, Lamarca R, de Miquel G, et al.Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in symptoms and health status in the ATTAIN Study [Abstract]. Chest 2011;140(4):547A.
31. Jones P, Bateman E, Singh D, Agusti A, Lamarca R, de Miquel G, et al.ATTAIN: Efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. Chest 2011;140(4):975A.
32. Jones PW, Agusti A, Bateman ED, Singh D, Lamarca R, de Miquel G, et al.Aclidinium bromide in patients with chronic obstructive pulmonary disease: Efficacy and safety results from ATTAIN [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A6350.
33. Jones PW, Agusti A, Bateman ED, Singh D, Lamarca R, de Miquel G, et al.Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28 2011;38(55):150s [P877].
34. Jones PW, Chuecos F, Lamarca R, Singh D, Agusti A, Bateman ED, et al.Unreported exacerbations of chronic obstructive pulmonary disease are associated with a reduction in health status: results from the ATTAIN study. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting abstracts):A6072.
35. Jones PW, Singh D, Agusti A, Bateman ED, Lamarca R, de Miquel G, et al.Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: results from ATTAIN [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1-5. 2012; Vol. 40, issue Suppl 56:9s [195].
36. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al.Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal 2012;40(4):830-6. [PUBMED: 22441743]
37. NCT01001494 . Efficacy and safety of aclidinium bromide at two dose levels versus placebo administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/study/NCT01001494 (accessed 1 May 2014).
38. Singh D, Bateman ED, Jones PW, Agusti A, Lamarca R, de Miquel G, et al.The ATTAIN study: bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Society Annual Congress; Sep 24-28; Amsterdam. 2011; Vol. 38, issue 55:149s [P875].
39. Singh D, Jones PW, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al.ATTAIN: Twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease [Abstract]. Thorax 2011;66 Suppl 4:A171 [P255].
40. D'Urzo A, Mergel V, Leselbaum A, Caracta C. Efficacy and safety of fixed-dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest 2013;144(4):1025A.
41. D'Urzo A, Rennard S, Mergel V, Garcia Gil E, Leselbaum A, Caracta C. The AUGMENT COPD trial: efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest 2014;145:426A.
42. NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437397 (accessed 1 May 2014).
43. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, et al.Efficacy and safety of aclidinium bromide compared with tiotropium and placebo in patients with moderate-to-severe COPD: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A4253.
44. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, et al.Efficacy of aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD: a phase IIIb study [Abstract]. Thorax 2012;67 Suppl 2:A26 [S51].
45. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, et al.Improvements in COPD symptoms and rescue medication use with aclidinium bromide compared with tiotropium and placebo: a phase IIIb study. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A4276.
46. Beier J, Kirsten AM, Mruz R, Segarra R, Chuecos F, Caracta C, et al.Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a six-week, randomised, controlled phase IIIb study. COPD 2013;10(4):511-22. [PUBMED: 23819698]
47. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, et al.Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: a phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sep 7-11; Barcelona. 2013; Vol. 42 Suppl 57:4s [185].
48. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, et al.Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study [Abstract]. European Respiratory Society Annual Congress; Sept 7-11; Barcelona. 2013; Vol. 42 Suppl 57:4s [184].
49. EUCTR2011-000834-12-DE . A multiple dose, double-blind, double-dummy, placebo controlled, parallel clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000834-12 (accessed 1 May 2014).
50. NCT01462929 . Efficacy and safety of aclidinium bromide 400 μg compared to placebo and to tiotropium bromide in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT01462929 (accessed 1 May 2014).
51. Chanez P, Burge PS, Dahl R, Creemers J, Chuchalin A, Lamarca R, et al.Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulmonary Pharmacology and Therapeutics 2010;23(1):15-21. [PUBMED: 19683590]
52. Chanez P, Burge S, Dahl R, Creemers J, Lamarca R, Garcia GE. Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:[A286].
53. Charez P, Burge S, Creemers J, Lamarca R, Garcia GE. Once daily administration of aclidinium bromide a novel long acting anticholinergic a phase II dose finding study [Abstract]. European Respiratory Society Annual Congress; Oct 4-8; Berlin. 2008:[2736].
54. Casaburi R, Maltais F, Celli B, Porszasz J, Garcia Gil E, Caracta C. Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. 2010:[5558].
55. Celli B, Maltais F, Casaburi R, Porszasz J, Garcia Gil E, Caracta C. Aclidinium bromide improves resting lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. 2010:[P1183].
56. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, et al.Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine 2011;105(4):580-7. [PUBMED: 21183326]
57. Maltais F, Celli B, Porszasz J, Casaburi R, Garcia GE, Caracta C. Aclidinium bromide improves exercise endurance, dyspnea and inspiratory capacity in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A4428.
58. NCT00500318 . A study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/study/NCT00500318 (accessed 1 May 2014).
59. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01572792 (accessed 1 May 2014).
60. EUCTR2007-004435-30-CZ . A randomised, four-week, placebo-controlled, double-blind, six arm parallel group, dose-finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 & 18μg) combined with the inhaled anticholinergic aclidinium bromide 200 μg, aclidinium bromide 200 μg monotherapy and formoterol 12 μg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-004435-30 (accessed 1 May 2014).
61. Sliwinski P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD [Abstract]. Thorax 2010;65 Suppl 4:P137.
62. D'Urzo A, Kerwin E, Donohue J, Rennard S, Gelb A, Lakkis H, et al.Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I [Abstract]. European Respiratory Society Annual Congress, Sep 1-5; Vienna. 2012; Vol. 40, issue Suppl 56:528s [P2890].
63. D'Urzo A, Kerwin E, Rennard S, He T, Garcia Gil E, Caracta C. Improvements in lung function with twice-daily aclidinium bromide: results of a long-term, phase 3 trial in patients with chronic obstructive pulmonary disease [Abstract]. Chest 2012;142(4_Meeting abstracts):740A.
64. D'Urzo A, Kerwin E, Rennard S, He T, Garcia Gil E, Caracta C. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD 2013;10(4):500-10. [PUBMED: 23679347]
65. D'Urzo A, Kerwin EM, Donohue JF, Rennard SI, Gelb AF, Lakkis H. Long-term extension study of ACCORD COPD I: effects of two doses of twice-daily aclidinium bromide in COPD patients [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185(Meeting Abstracts):A2913.
66. Gelb A, D'Urzo A, Tashkin D, Zhong X, Gil EG, Caracta C. Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two one-year studies. Chest 2012;142(4_Meeting abstracts):691A.
67. NCT00970268 . Long-term extension study of the safety, tolerability, and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-36). http://www.clinicaltrials.gov/ct2/show/study/NCT00970268 (accessed 1 May 2014).
68. D'Urzo A, Jones P, Ferguson G, Rekeda L, Gil EG, Caracta C. Aclidinium bromide improves lung function in a wide range of patients with moderate to severe COPD: Pooled subgroup analysis of the ACCORD COPD I and II and ATTAIN trials. Chest 2013;144(4_Meeting abstracts):746A.
69. D'Urzo A, Rennard S, Jones P, Rekeda L, Gil EG, Caracta C. Exposure-adjusted anticholinergic adverse events following long-term treatment with aclidinium bromide in patients with COPD. Chest 2013;144(4_Meeting abstracts):717A.
70. de Miquel G, Schrodter A, Miletzki B, Gurniak M, Serra C, Jansat JM. Low systematic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:Poster #F53.
71. Donohue J, Tashkin D, Ferguson G, Kowey P, Rekeda L, Shrestha P, et al.Long-term cardiovascular safety of aclidinium bromide in patients with COPD. Chest 2013;144(4_Meeting abstracts):716A.
72. A multiple dose, double-blind, double-dummy, three period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 μg given either in the morning or in the evening in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-000010-36 (accessed 1 May 2014).
73. A phase IIa, randomised, multicentre, evaluator-blinded, four-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formoterol 12 μg once daily delivered by two different dry powder inhalers (Aerolizer® and Almirall inhaler), of the fixed dose combination formoterol 12 μg + aclidinium bromide 200 μg once daily delivered by Almirall inhaler, and of formoterol 12 μg twice daily delivered by Aerolizer®, in moderate to severe chronic obstructive pulmonary disease patients. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-003648-31 (accessed 1 May 2014).
74. Ferguson G, Kerwin E, Singh D, Kowey P, Rekeda L, Shrestha P, et al.Cardiovascular safety of aclidinium bromide in COPD: pooled results from three placebo-controlled studies. Chest 2013;144(4_Meeting abstracts):715A.
75. Flach S, Jansat JM, Ho J, Garcia GE, Caracta C, Ortiz S. Metabolism and excretion of aclidinium bromide following intravenous administration of [14C] aclidinium bromide in healthy subjects [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A4463.
76. Fuhr R, Magnussen H, Ribera A, Kirsten A, Falques M, Caracta C, et al.Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; 2010 September 18-22; Barcelona, Spain. 2010:[P1236].
77. Fuhr R, Magnussen H, Ribera A, Kirsten A-M, Falques M, Caracta C, et al.Efficacy and safety of twice-daily aclidinium bromide 400 μg compared with placebo and tiotropium 18 μg once daily in moderate to severe COPD patients [Abstract]. Chest 2010;138(4):465A.
78. Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, et al.Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012;141(3):745-52. [PUBMED: 21903737]
79. NCT00868231 . Efficacy of aclidinium bromide administered in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/NCT00868231 (accessed 1 May 2014).
80. Gelb A, D'Urzo A, Tashkin D, Zhong X, Gil EG, Caracta C. Effects of aclidinium bromide in patients with chronic obstructive pulmonary disease: clinically significant improvements in health status in two 1-year studies. Chest 2012;142(4_Meeting abstracts):691A.
81. Gelb A, Tashkin D, Make B, Zhong X, Garcia Gil E, Caracta C. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respiratory Medicine 2013;107(12):1957-65.
82. Gelb A, Tashkin D, Make B, Zhong X, Garcia Gil E, Caracta C. Long-term safety of twice-daily aclidinium bromide in COPD patients: a one-year, double-blind study [Abstract]. European Respiratory Society Annual Congress; Sep 1-5; Vienna. 2012; Vol. 40 (Suppl 56):376s [P2118].
83. Gelb AF, Make BJ, Tashkin DP, Zhong X, Garcia GE, Caracta C. Long-term efficacy and safety of twice-daily aclidinium bromide in COPD patients: a one-year Study [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185 (Meeting Abstracts):A2256.
84. NCT01044459 . Long-term safety, tolerability and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAS-MD-35). http://www.clinicaltrials.gov/ct2/show/study/NCT01044459 (accessed 1 May 2014).
85. Tashkin D, Gelb A, Make B, Zhong X, Garcia Gil E, Caracta C. Long-term efficacy of twice-daily aclidinium bromide in COPD patients: a one-year study [Abstract]. European Respiratory Society Annual Congress; Sep 1-5; Vienna. 2012; Vol. 40 (Suppl 56):528s [P2893].
86. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics 2009;47(7):460-8. [PUBMED: 19640353]
87. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. Journal of Clinical Pharmacology 2009;49(10):1239-46. [PUBMED: 19592595]
88. Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, et al.Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine 2010;104(6):865-72. [PUBMED: 20044242]
89. Joss G, Schelflout V, Kanniess F, Ludwig-Segpiel A, Garcia Gil E, Massana Montejo E. Bronchodilator effects of aclidinium bromide a novel long-acting anticholinergic in COPD patients a phase II study [Abstract]. European Respiratory Journal 2007;30 Suppl 51:210s [1299].
90. EUCTR2009-015901-38-DE . Efficacy, safety and tolerability of two fixed-dose combinations of aclidinium bromide with two doses of formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo all administered twice daily in stable, moderate to severe chronic obstructive pulmonary disease patients. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015901-38 (accessed 1 May 2014).
91. Kerwin E, Lapidus R, Leselbaum A, Ortiz S, Rowe P, Caracta C. Dose-ranging study of two fixed-dose combinations of twice-daily aclidinium bromide plus formoterol in patients with moderate to severe COPD. Chest 2013;144(4_Meeting Abstracts):747A.
92. NCT01049360 . Efficacy and safety study of two fixed-dose combinations of aclidinium bromide with formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo (LAC-MD-27). http://clinicaltrials.gov/ct2/show/NCT01049360 (accessed 1 May 2014).
93. Lasseter KC, Aubets J, Chuecos F, Garcia GE. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. Journal of Clinical Pharmacology 2011;51(6):923-32.
94. Lasseter KC, Aubets J, Garcia GE. Aclidinium bromide a novel long acting anticholinergic does not affect QT interval in healthy subjects [Abstract]. American Thoracic Society International Conference; May 16-21; Toronto. 2008:A655[#F54].
95. Lasseter K, Dilzer S, Jansat JM, Garcia GE, Caracta CF, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulmonary Pharmacology and Therapeutics 2012;25(2):193-9. [PUBMED: 22366196]
96. Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta C, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A1615.
97. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, et al.Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respiratory Medicine 2009;103(12):1832-7. [PUBMED: 19651504]
98. EUCTR2008-006886-10-DE . A multiple dose, double blind, double-dummy, two-week three way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled aclidinium bromide 400 μg compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006886-10 (accessed 1 May 2014).
99. Magnussen H, Ribera LA, Kirsten AM, Falques M, Caracta C, Garcia GE. Efficacy and safety of aclidinium bromide 400 g twice daily compared with placebo and tiotropium in patients with moderate to severe COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A4440.
100. EUCTR2005-005804-17-NL . A single dose, double-blind, double-dummy, three period cross-over, placebo controlled clinical trial to assess the rate of onset of action of inhaled LAS 34273 200 μg compared to placebo and tiotropium 18 μg in patients with chronic obstructive pulmonary disease (COPD). http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2005-005804-17-NL or https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005804-17.
101. NCT00435760 . Clinical trial to assess rate of onset of bronchodilator action in severe stable chronic obstructive pulmonary disease (COPD) patients. http://clinicaltrials.gov/ct2/show/study/NCT00435760 (accessed 2 May 2014).
102. NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. http://clinicaltrials.gov/ct2/show/NCT00626522 (accessed 2 May 2014).
103. NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT00706914 (accessed 2 May 2014).
104. NCT01078623 . Efficacy and safety of two fixed dose combinations of aclidinium bromide with formoterol fumarate (ALIGHT-COPD). http://clinicaltrials.gov/show/NCT01078623 (accessed 2 May 2014).
105. Make B, Donohue J, Zhong X, Leselbaum A, Caracta C. Long-term safety of a fixed-dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest 2014;145:386A.
106. NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). http://clinicaltrials.gov/ct2/show/study/NCT01437540 (accessed 2 May 2014).
107. NCT01551888 . Pharmacokinetic, safety and tolerability study of aclidinium/formoterol fixed dose combination and formoterol in patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01551888 (accessed 2 May 2014).
108. EUCTR2013-000116-14-HU . A randomised, double-blind, double-dummy, active-controlled study evaluating the efficacy, safety and tolerability of twice-daily aclidinium bromide /formoterol fumarate compared with twice-daily salmeterol/fluticasone propionate for 24-weeks treatment in symptomatic patients with chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-000116-14 (accessed 2 May 2014).
109. NCT01908140 . Study of aclidinium bromide/formoterol fumarate compared with salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01908140 (accessed 2 May 2014).
110. NCT01915784 . Preference, satisfaction and ease of use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) inhalers in patients with COPD. http://clinicaltrials.gov/ct2/show/NCT01915784 (accessed 2 May 2014).
111. NCT02038829 . A dose-range finding study of SUN-101 in subjects with moderate to severe COPD (GOLDEN 6). http://clinicaltrials.gov/ct2/show/NCT02038829 (accessed 2 May 2014).
112. NCT02039050 . Evaluation of long-acting muscarinic antagonists in COPD (MAN04). http://clinicaltrials.gov/ct2/show/NCT02039050 (accessed 2 May 2014).
113. Ortiz S, Flach S, Caracta C, Garcia GE, Jansat JM. Safety and tolerability of aclidinium bromide administered intravenously and absolute bioavailability of inhaled aclidinium bromide in healthy subjects [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A4464.
114. Ortiz S, Flach S, Caracta C, Garcia Gil E, Jansat J. Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects [Abstract]. European Respiratory Society Annual Congress; Sep 18-22; Barcelona. 2010:[P1180].
115. Schelfhout VJ, Ferrer P, Jansat JM, Peris F, Gil EG, Pauwels RA, et al.Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. British Journal of Clinical Pharmacology 2010;69(5):458-64. [PUBMED: 20573081]
116. Schelfhout VJ, Joos GF, Ferrer P, Kannies F, Luria X, Richter K, et al.Activity of LAS34273, a new long acting anticholinergic antagonist, in COPD patients [abstract]. American Thoracic Society 99th International Conference; May 16-21; Seattle. 2003; Vol. B024 Poster 44.
117. Schelfhout VJ, Joos GF, Garcia Gil E, Montejo EM. Bronchodilator/broncho-protective effects of aclidinium bromide, a novel long-acting anticholinergic:a phase I study. European Respiratory Journal 2007;30 Suppl 51:356S.
118. Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator in chronic obstructive pulmonary disease (COPD) patients. http://www.clinicaltrials.gov/ct2/show/NCT01120093 (accessed 2 May 2014).
119. EUCTR2009-017380-42-DE . Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator all administered twice daily by inhalation in patients with stable moderate and severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017380-42 (accessed 2 May 2014).
120. Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, et al.A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulmonary Pharmacology and Therapeutics 2012;25(3):248-53. [PUBMED: 22497752]
121. Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, et al.Corrigendum to " A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients" [Pulm Pharmacol Ther 25 (3) (2012) 248-53]. Pulmonary Pharmacology and Therapeutics 2013;26(2):305.
122. Singh D, Magnussen H, Kirsten A, Mindt-Pruefert S, Caracta C, Jarreta D, et al.Aclidinium bromide: a phase IIB, dose-finding study [Abstract]. Thorax 2011;66 Suppl 4:A172 [P256].
123. NCT01385696 . Study evaluating preference, satisfaction and ease of use of inhalers in chronic obstructive pulmonary disease (COPD) diagnosed patients. http://clinicaltrials.gov/ct2/show/NCT01385696 (accessed 2 May 2014).
124. van der Palen J, Ginko T, Kroker A, van der Valk P, Goosens M, Padulles L, et al.Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opinion on Drug Delivery 2013;10(8):1023-31.
125. van der Palen J, Ginko T, Kroker A, van der Valk P, GoosensM, Padulles L, et al.Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD. European Respiratory Journal 2012;40 Suppl 56:389s.
126. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010;7(5):331-6. [PUBMED: 20854047]
127. Vestbo J, Vogelmeier C, Creemers J, Ribera A, Garcia Gil E. Fast onset of effect of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with COPD [Abstract]. Thorax 2009;64 Suppl IV:A167 [P212].
128. Vestbo J, Vogelmeier C, Creemers J, Ribera A, Garcia Gil E. Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist [Abstract]. European Respiratory Society Annual Congress; Sep 12-16; Vienna. 2009:[E4362].
129. Beeh KM, Watz H, Magnussen H, Puente-Maestu L, Jarreta D, Caracta C, et al.Aclidinium bromide improves exercise endurance and dynamic hyperinflation and decreases exertional dyspnoea in patients with moderate-to-severe COPD. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A2430.
130. Beeh KM, Watz H, Magnussen H, Puente-Maestu L, Jarreta D, Caracta C, et al.Effects of aclidinium bromide on exercise endurance, dynamic hyperinflation, physical activity and exertional dyspnoea in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress, Sep 7-11; Barcelona. 2013; Vol. 42 Suppl 57:636s [3035].
131. EUCTR2011-002665-38-DE . A multiple dose, randomised, double-blind, placebo controlled, two period crossover clinical trial to assess the effect of aclidinium bromide 400 μg bid on exercise endurance in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002665-38 (accessed 2 May 2014).
132. NCT01471171 . Efficacy and safety of aclidinium bromide 400 μg BID (twice a day) compared to placebo in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT01471171 (accessed 2 May 2014).
133. Watz H, Beeh KM, Magnussen H, De Teres L, Jarreta D, Caracta C, et al.Aclidinium bromide improves static lung function and hyperinflation in patients with moderate-to-severe COPD. American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A2431.
134. Watz H, Beeh KM, Magnussen H, de Theresa L, Jarreta D, Caracta C, et al.Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 7-11; Barcelona. 2013; Vol. 42 Suppl 57:981s [4633].
135. NCT01636401 . Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/ct2/show/NCT01636401 (accessed 1 May 2014).
136. NCT01966107 . Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). http://clinicaltrials.gov/ct2/show/NCT01966107 (accessed 1 May 2014).
137. Alagha K, Bourdin A, Tummino C, Chanez P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Therapeutic Advances in Respiratory Disease 2011;5(1):19-28. [PUBMED: 20884687]
138. Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, et al.Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease 2014; Vol. 5, issue 2:85-98. [PUBMED: 24587893]
139. Almirall . Clinical trial results. http://www.almirall.com/webcorp2/cda/ImD_04_03.jsp?fMarc= (accessed 11 April 2014).
140. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al.Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine 2011;155(3):179-91.
141. Hoyert DL, Xu J. Deaths: preliminary data for 2011 (National Vital Statistics Reports). http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf (accessed 25 December 2012).
142. Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD002309.pub2]
143. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2]
144. Cranston JM, Crockett A, Moss J, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001744.pub2]
145. Effing T, Monninkhof EEM, van der Valk PPDLPM, Zielhuis GGA, Walters EH, van der Palen JJ, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2]
146. United States Food, Drug Administration (FDA). Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000TOC.cfm (accessed 25 December 2012).
147. Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. http://www.forestpharm.com/ (accessed 25 December 2012).
148. Gavaldà A, Garcia-Gil E. Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA). New drugs and targets for asthma and COPD. Progress in Respiratory Research 2010;39:33-8.
149. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Global strategy for diagnosis, management and prevention of COPD. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed 14 February 2013).
150. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. www.cochrane-handbook.org.
151. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology: Mechanisms of Disease 2009;4:435-59.
152. Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD008250.pub2]
153. Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/ (accessed 25 December 2012). [DOI: 10.1186/1465-9921-12-55]
154. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al.Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal 2012;40(4):830-6. [PUBMED: 22441743]
155. Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Advances in Therapy 2013;30(4):354-68. [PUBMED: 23553509]
156. Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 2013;8:405-23. [PUBMED: 24043936]
157. Karakiulakis G, Roth M. Muscarinic receptors and their antagonists in COPD: anti-inflammatory and anti-remodeling effects. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512336/ (accessed 25 December 2012). [DOI: 10.1155/2012/409580]
158. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009285.pub2]
159. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD003793.pub2]
160. MacNee W. ABC of chronic obstructive pulmonary disease: pathology, pathogenesis, and pathophysiology. BMJ 2006;332:1202-4.
161. Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 2012;6(6):345-61. [PUBMED: 23075544]
162. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2]
163. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. http://guidance.nice.org.uk/CG101/Guidance/pdf/English (accessed 25 December 2012).
164. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 25 December 2012).
165. Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD002733.pub2]
166. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD001287.pub4]
167. Ram FSF, Jones P, Jardim J, Castro AA, Atallah ÁN, Lacasse Y, et al.Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003902]
168. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
169. Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:457-66. [PUBMED: 22003291]
170. Suppli Ulrik C. Aclidinium bromide: clinical benefit in patients with moderate to severe COPD. The Open Respiratory Medicine Journal 2012;6:150-4. [PUBMED: 23264836]
171. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. New England Journal of Medicine 2004;350(26):2689-97. [PUBMED: 15215485]
172. Tiong LU, Gibson PG, Hensley MJ, Hepworth R, Lasserson TJ, Smith B, et al.Lung volume reduction surgery for diffuse emphysema. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001001.pub2]
173. Abramson M, Crockett AJ, Dabscheck E, Frith PA, George J, Glasgow N, et al.on behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Version 2.35 2013. http://www.copdx.org.au/ (accessed 14 February 2014).
174. van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD002999]
175. Vogelmeier C, Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 2011;5(3):163-73. [PUBMED: 21511677]
176. Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD005374]
177. Walters JAE, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD001390.pub2]
178. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD007891.pub2]
179. World Health Organization. The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (accessed 25 December 2012).
180. World Health Organization. Global status report on noncommunicable diseases 2010. http://www.who.int/nmh/publications/ncd_report2010/en/ (accessed 25 December 2012).
181. World Health Organization. Chronic obstructive pulmonary disease. http://www.who.int/respiratory/copd/en (accessed 25 December 2012).
182. World Health Organization. COPD predicted to be third leading cause of death in 2030. http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/index.html# (accessed 25 December 2012).
183. World Health Organization. International Clinical Trials Registry Platform (ICTRP) search portal. http://apps.who.int/trialsearch/ (accessed 2 May 2014).
184. Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. The Annals of Pharmacotherapy 2013;47(7-8):1017-28. [PUBMED: 23737515]
185. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3]